1. Home
  2. IRMD vs PHAT Comparison

IRMD vs PHAT Comparison

Compare IRMD & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iRadimed Corporation

IRMD

iRadimed Corporation

HOLD

Current Price

$98.07

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$13.60

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IRMD
PHAT
Founded
1992
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
IRMD
PHAT
Price
$98.07
$13.60
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$72.00
$17.33
AVG Volume (30 Days)
77.2K
1.4M
Earning Date
02-05-2026
03-05-2026
Dividend Yield
0.69%
N/A
EPS Growth
13.00
N/A
EPS
1.65
N/A
Revenue
$80,511,268.00
$147,190,000.00
Revenue This Year
$15.17
$221.76
Revenue Next Year
$10.15
$81.67
P/E Ratio
$59.33
N/A
Revenue Growth
12.91
460.30
52 Week Low
$47.48
$2.21
52 Week High
$104.93
$18.31

Technical Indicators

Market Signals
Indicator
IRMD
PHAT
Relative Strength Index (RSI) 48.07 41.11
Support Level $96.46 $13.14
Resistance Level $104.93 $14.31
Average True Range (ATR) 2.82 0.92
MACD -0.68 -0.15
Stochastic Oscillator 21.02 15.13

Price Performance

Historical Comparison
IRMD
PHAT

About IRMD iRadimed Corporation

iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: